Adicet bio announces oral presentation of updated adi-001 phase 1 data at the 2022 american society of clinical oncology (asco) annual meeting

Menlo park, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (car) t cell therapies for cancer, today announced that updated safety and efficacy data from the phase 1 study of adi-001 for the potential treatment of relapsed or refractory b-cell non-hodgkin's lymphoma (nhl) will be delivered as an oral presentation at the upcoming 2022 american socie
ACET Ratings Summary
ACET Quant Ranking